Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca Rocca

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
Molecular Interventions|March 28, 2006
Targeting PGE2 receptor subtypes rather than cyclooxygenases: a bridge over troubled water?Bianca Rocca
European Heart Journal. Cardiovascular Pharmacotherapy|May 19, 2026
Innovation and constraints in cardiovascular pharmacotherapyBianca Rocca
Arteriosclerosis, Thrombosis, and Vascular Biology|January 5, 2008
Aspirin: promise and resistance in the new millenniumCarlo Patrono, Bianca Rocca
Frontiers in Pharmacology|November 19, 2019
Measurement of Thromboxane Biosynthesis in Health and DiseaseCarlo Patrono, Bianca Rocca
Nature Clinical Practice. Rheumatology|April 5, 2007
Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?Bianca Rocca, Giovanni Davì
Annual Review of Medicine|January 12, 2010
The future of antiplatelet therapy in cardiovascular diseaseCarlo Patrono, Bianca Rocca
Thrombosis|January 31, 2012
Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanismsBianca Rocca, Giovanna Petrucci
European Heart Journal|August 3, 2015
Platelet progenitors: the hidden drug targetBianca Rocca, Carlo Patrono
Drugs & Aging|March 5, 2016
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary SyndromesBianca Rocca, Steen Husted
Journal of the American College of Cardiology|July 14, 2022
Less Thromboxane, Longer LifeCarlo Patrono, Bianca Rocca
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
Molecular Interventions|March 28, 2006
Targeting PGE2 receptor subtypes rather than cyclooxygenases: a bridge over troubled water?Bianca Rocca
European Heart Journal. Cardiovascular Pharmacotherapy|May 19, 2026
Innovation and constraints in cardiovascular pharmacotherapyBianca Rocca
Arteriosclerosis, Thrombosis, and Vascular Biology|January 5, 2008
Aspirin: promise and resistance in the new millenniumCarlo Patrono, Bianca Rocca
Frontiers in Pharmacology|November 19, 2019
Measurement of Thromboxane Biosynthesis in Health and DiseaseCarlo Patrono, Bianca Rocca
Nature Clinical Practice. Rheumatology|April 5, 2007
Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?Bianca Rocca, Giovanni Davì
Annual Review of Medicine|January 12, 2010
The future of antiplatelet therapy in cardiovascular diseaseCarlo Patrono, Bianca Rocca
Thrombosis|January 31, 2012
Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanismsBianca Rocca, Giovanna Petrucci
European Heart Journal|August 3, 2015
Platelet progenitors: the hidden drug targetBianca Rocca, Carlo Patrono
Drugs & Aging|March 5, 2016
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary SyndromesBianca Rocca, Steen Husted
Journal of the American College of Cardiology|July 14, 2022
Less Thromboxane, Longer LifeCarlo Patrono, Bianca Rocca
Pageof 16